A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan’s Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development.
The deal comes a
Continue Reading on South China Morning Post
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.